Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients

  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Huang, Xin-En (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2015.04.29


Objective: To explore the association of serum tumor abnormal protein (TAP) with other serological biomarkers e.g. carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9) and its clinical application in colorectal cancer (CRC) patients. Methods: Patients (N=98) were enrolled into this study with histologically or cytologically confirmed CRC. Using a test kit, the level of TAP was determined, while chemiluminescence was used to measure the levels of some other common serological biomarkers e.g. CEA, CA125 and CA19-9. Results: The area of TAP condensed particulate matter decreased after chemotherapy compared with before chemotherapy when CT or MRI scans showed disease control. In contrast, it increased with disease progression (P<0.05). Furthermore, a statistically significant difference was confirmed in monitoring of TAP and common serological biomarkers e.g. CEA and CA19-9 (p<0.05). Conclusions: Detecting TAP in CRC patients has high sensitivity and specificity and can be used as a new independent indicator for clinically monitoring CRC patients in the course of chemotherapy.


Tumor abnormal protein (TAP);serological biomarkers;colorectal cancer (CRC)


  1. Bast RC Jr, Klug TL, St John E, et al (1983). A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309, 883-7.
  2. Brenner H, Kloor M, Pox CP (2014). Colorectal cancer. Lancet, 383, 1490-502.
  3. Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.
  4. Coghlin C, Murray GI (2013). Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics, 13, 2227-8.
  5. Eleftheriadis N, Papaloukas C, Pistevou-Gompaki K (2009). Diagnostic value of serum tumor markers in asymptomatic individuals. J Buon, 14, 707-10.
  6. Elmunzer BJ, Hayward RA, Schoenfeld PS, et al (2012). Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med, 9, e1001352.
  7. Ferlay J, Shin HR, Bray F, et al ( 2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  8. Filella X, Molina R, Grau JJ, et al (1992). Prognostic value of CA 19-9 levels in colorectal cancer. Ann Surg, 216, 55-9.
  9. Gehan EA, Tefft MC (2000). Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81.
  10. Goldberg EM, Simunovic LM, Drake SL, et al (1989). Comparison of serum ca 19-9 and cea levels in a population at high risk for colorectal cancer. Hybridoma, 8, 569-75.
  11. Grutzmann R, Molnar B, Pilarsky C, et al (2008). Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One, 3, e3759.
  12. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008). Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol, 103, 1541-9.
  13. Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7.
  14. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
  15. Jemal A, Bray F, CenterMMet al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  16. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5.
  17. Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008). Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep, 41, 685-92.
  18. Lee BB, Lee EJ, Jung EH, et al (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res, 15, 6185-91.
  19. Li YH, An X, Xiang XJ (2009). Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy [in Chinese]. Ai Zheng, 28, 939-44.
  20. Liu J, Huang XE (2014). Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
  21. Lu YY, Huang XE, et al (2014). Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev, 15, 3335-41.
  22. Luo Y, Wang L, Wang J (2013). Developing proteomicsbased biomarkers for colorectal neoplasms for clinical practice:opportunities and challenges. Proteomics Clin Appl, 7, 30-41.
  23. Martínez-Aguilar J, Chik J, Nicholson J, et al (2013). Quantitative mass spectrometry for colorectal cancer proteomics. Proteomics Clin Appl, 7, 42-54.
  24. McKeown E, Nelson DW, Johnson EK, et al (2014). Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer, 5, 31-43
  25. Migliore L, Migheli F, Spisni R, Coppede F (2011). Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol, 2011, 792362.
  26. Newton KF, Newman W, Hill J (2012). Review of biomarkers in colorectal cancer. Colorectal Dis, 14, 3-17.
  27. Perkins GL, Slater ED, Sanders GK, et al (2003). Serum tumor markers. Am Fam Physician, 68, 1075-82.
  28. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  29. Sorbye H, Dahl O (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol, 43, 495-8.
  30. Tian GY, Miu M, Huang XE (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8.
  31. Wang L, Huang XE (2015). Clinical study on safety and efficacy of JiSaiXin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for Chinese undergoing chemotherapy. Asian Pac J Cancer Prev, 16 299-301.
  32. Winawer S, Fletcher R, Rex D, et al (2003). Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology, 124, 544-60.
  33. Wu XY, Huang XE (2015). Screening for patients with non-small cell lung cancer who could survive long term chemotherapy. Asian Pac J Cancer Prev, 16, 647-52.
  34. Wu XY, Huang XE, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4.
  35. Xu D, Li XF, Zheng S, Jiang WZ (2006). Quantitative real-time RTPCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. J Zhejiang Univ Sci, B7, 445-51.
  36. Yang L, Sun Y, Huang XE, Yu DS, et al (2015). Carcinoma Microsatellite Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Stage II Rectal Cancer. Asian Pac J Cancer Prev, 16, 1545-51.
  37. Zieglschmid V, Hollmann C, Bocher O (2005). Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci, 42, 155-96.

Cited by

  1. Diet and Colorectal Cancer Risk in Asia - a Systematic Review vol.16, pp.13, 2015,
  2. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016,
  3. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016,
  4. Prognostic value of serum tumor abnormal protein in gastric cancer patients vol.5, pp.1, 2016,